The development of novel antiandrogens and androgen synthesis inhibitors has improved the outcomes of patients with prostate cancer; however, the issue of resistance to these therapies has also emerged. In light of these developments, unexpected interactions between these novel therapies and glucocorticoid signalling have been observed. Here, authors describe current knowledge of androgen–glucocorticoid signalling as a cause of drug resistance and disease progression in patients with prostate cancer.
- Sujata Narayanan
- Sandy Srinivas
- David Feldman
